Edition:
India

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

216.71USD
22 Mar 2019
Change (% chg)

$-10.17 (-4.48%)
Prev Close
$226.88
Open
$225.00
Day's High
$226.80
Day's Low
$216.49
Volume
2,774,114
Avg. Vol
584,555
52-wk High
$388.67
52-wk Low
$216.49

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $69,239.67
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 21.50 29.30 32.54
EPS (TTM): 15.23 -- --
ROI: 17.59 14.23 13.82
ROE: 28.64 15.46 15.24

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

22 Mar 2019

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

22 Mar 2019

Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trials

TOKYO Eisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orders after the Japanese drugmaker and its partner Biogen Inc said they are ending two drug trials of their experimental Alzheimer's disease drug aducanumab.

22 Mar 2019

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

CHICAGO/TOKYO Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday. | Video

22 Mar 2019

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

CHICAGO/TOKYO Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday. | Video

22 Mar 2019

UPDATE 3-Biogen scraps Alzheimer drug trials, wiping $17 billion off its market value

* Analysts question Biogen's growth prospects (Adds context, details, background)

21 Mar 2019

Biogen, Eisai scrap Alzheimer drug trials

March 21 Biogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.

21 Mar 2019

Japan's Fujifilm buys biologics unit from Biogen to boost healthcare business

TOKYO Japan's Fujifilm Holdings Corp will buy a drugmaking business from U.S.-based Biogen Inc for about $890 million to try to bolster its healthcare business as growth at its legacy photocopy operations stagnates.

12 Mar 2019

Japan's Fujifilm buys biologics unit from Biogen to boost healthcare business

TOKYO Japan's Fujifilm Holdings Corp will buy a drugmaking business from U.S.-based Biogen Inc for about $890 million to try to bolster its healthcare business as growth at its legacy photocopy operations stagnates.

12 Mar 2019

UPDATE 2-Japan's Fujifilm buys biologics unit from Biogen to boost healthcare business

* Fujifilm expects 100 bln yen revenue from CDMO business by 2021 (Adds details and background)

12 Mar 2019

Earnings vs. Estimates